Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.51 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.51 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.51 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 10/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.43 |
| ▸ | HPGD | P15428 | 7/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 6/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.40 |
| ▸ | NPC1 | O15118 | 6/20 | 0.38 |
| ▸ | RAB9A | P51151 | 6/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | AHR | P35869 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20223634 | 0.77 | KDM4E (0.50) | CHEK1LIMK1DYRK1ACLK4KDM4E | |
| SCHEMBL11403967 | 0.77 | CHEK1 (0.73) | CHEK1LIMK1DYRK1ACLK4KDM4E | |
| SCHEMBL7332574 | 0.75 | CHEK1 (0.49) | CHEK1LIMK1DYRK1ACLK4KDM4E | |
| SCHEMBL1338053 | 0.74 | KDM4E (0.68) | CHEK1LIMK1DYRK1ACLK4KDM4E | |
| SCHEMBL15358474 | 0.73 | TSHR (0.39) | CHEK1LIMK1DYRK1ACLK4KDM4E | |
| SCHEMBL5045177 | 0.72 | — | — | |
| SCHEMBL7632455 | 0.69 | DYRK1A (0.39) | CHEK1LIMK1DYRK1ACLK4KDM4E | |
| SCHEMBL15401844 | 0.68 | — | — | |
| SCHEMBL2628994 | 0.68 | — | — | |
| SCHEMBL7331691 | 0.68 | CHEK1 (0.49) | CHEK1LIMK1DYRK1ACLK4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013075173-A1 | COMPOUNDS FOR THE TREATMENT OF HCV | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2013-05-30 | — | — | WO | claimed |
| US-12509424-B2 | Compound and composition as PDGF receptor kinase inhibitor | NIPPON SHINYAKU CO., LTD. (JP) | 2025-12-30 | — | — | US | disclosed |
| US-11701345-B2 | Car activator agents for cyclophosphamide-based treatments of cancer | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230101484-A1 | COMPOUND AND COMPOSITION AS PDGF RECEPTOR KINASE INHIBITOR | NIPPON SHINYAKU CO., LTD. (JP) | 2023-03-30 | — | — | US | disclosed |
| EP-2875029-B1 | 5,5-HETEROAROMATIC ANTI-INFECTIVE COMPOUNDS | MORASKI GARRETT (US) | 2021-11-10 | — | — | EP | disclosed |
| US-20200352915-A1 | CAR ACTIVATOR AGENTS FOR CYCLOPHOSPHAMIDE-BASED TREATMENTS OF CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-11-12 | — | — | US | disclosed |
| US-9605002-B2 | 5,5-heteroaromatic anti-infective compounds | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2017-03-28 | — | — | US | disclosed |
| US-20150210715-A1 | 5,5-HETEROAROMATIC ANTI-INFECTIVE COMPOUNDS | UNIVERSITY OF NOTRE DAME DU LAC | 2015-07-30 | — | — | US | disclosed |
| EP-2875029-A2 | 5,5-HETEROAROMATIC ANTI-INFECTIVE COMPOUNDS | Moraski, Garrett (US) | 2015-05-27 | — | — | EP | disclosed |
| WO-2014015167-A2 | 5,5-HETEROAROMATIC ANTI-INFECTIVE COMPOUNDS | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2014-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11701345-B2 | Car activator agents for cyclophosphamide-based treatments of cancer | CYP2A6, CYP2B6, CYP4A11 | CHEK1 689/4885LIMK1 4229/4885DYRK1A 2831/4885 |
| US-12509424-B2 | Compound and composition as PDGF receptor kinase inhibitor | PDGFRA, PDGFRB, PDGFA | CHEK1 977/4885LIMK1 1682/4885DYRK1A 3583/4885 |
| US-20200352915-A1 | CAR ACTIVATOR AGENTS FOR CYCLOPHOSPHAMIDE-BASED TREATMENTS OF CANCER | CYP2A6, CYP2B6, CYP4A11 | CHEK1 689/4885LIMK1 4229/4885DYRK1A 2831/4885 |
| US-20230101484-A1 | COMPOUND AND COMPOSITION AS PDGF RECEPTOR KINASE INHIBITOR | PDGFRB, PDGFRA, PDGFA | CHEK1 1310/4885LIMK1 1015/4885DYRK1A 2041/4885 |
| US-20150210715-A1 | 5,5-HETEROAROMATIC ANTI-INFECTIVE COMPOUNDS | API5, CASP5, IL5 | CHEK1 1166/4885LIMK1 2541/4885DYRK1A 1875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.